ClinicalTrials.gg
Status unknownNCT04000295Updated Oct 8, 2019

Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer

A Phase 3 interventional study of Apatinib and Etoposide in Ovarian Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-08.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2019), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing apatinib in Ovarian Neoplasms — 6 open to participants now, 6 under way, 1 of them phase 3. apatinib · Ovarian Neoplasms.

Planned enrollment
2nd of 22
280 · median 59
Started
2019
with 2 others
Phase 3
3 of 22
1 open now
Registered
11th of 22
by date
Lead sponsor
5 of 22
Jiangsu HengRui Medicine Co., Ltd.

Among the 22 studies testing apatinib in Ovarian Neoplasms, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2019, is one of 3 in phase 3, and was the 11th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

6 of the 22 studies testing apatinib in Ovarian Neoplasms are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

About apatinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing apatinib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

The study is conducted to evaluate the efficacy, safety and tolerability of apatinib (375 mg qd) and etoposide capsule (50 mg/d, d1-14, q3w) in subjects with platinum resistant or refractory ovarian cancer compared with weekly paclitaxel (80 mg/m2, d1, d8, d15, q3w).

03

Conditions studied

  • Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 Years and older
  2. Epithelial ovarian, fallopian tube or primary peritoneal cancer
  3. Platinum and resistant disease (disease progression during platinum therapy or within 6 months of platinum therapy)
  4. EOCG performance status of 0-1

Exclusion criteria

Exclusion Criteria:

  1. Uncontrolled hypertension ( systolic ≥140 mmHg or diastolic ≥90 mmHg despite antihypertensive therapy)
  2. Known to any of the study drugs or .
  3. Known hereditary or acquired bleeding and thrombotic tendencies (e.g. hemophiliacs, coagulation disorders, thrombocytopenia, etc.);
  4. Congenital or acquired immune deficiency (e.g. infected)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    Apatinib and Etoposide capsule

    Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity

    Drug: Apatinib · Drug: Etoposide

  • Active comparator
    Weekly Paclitaxel

    Weekly Paclitaxel (80 mg/m2, d1, d8, d15, q3w) until disease progression or intolerable toxicity

    Drug: Paclitaxel

Interventions

  • Subjects receive Apatinib orally, Dosage form: tablet, Strength: 375 mg/d

  • Subjects receive Etoposide capsule orally, d1-14, q3w, Dosage form: capsule, Strength: 50 mg/d

  • Subjects receive Weekly Paclitaxel, intravenously, d1, d8, d15, q3w, Dosage form: injectable, Strength: 80 mg/m2

06

What researchers measure

Primary outcomes

  1. Progression free survival(PFS) by independent review committee(IRC)

    PFS was defined as the time from the date of randomization to the first documented disease progression or death, whichever occurred first. Progression was based on tumor assessment made by the IRC according to the RECIST criteria

    Time frame: up to approximately 2 years

Secondary outcomes

  1. The incidence and severity of adverse events (AEs) and serious adverse events (SAEs)

    Frequency and severity of Adverse Events or Serious Adverse Events as defined by CTCAE version 5.0

    Time frame: up to approximately 2 years

  2. PFS by investigator

    PFS was defined as the time from the date of randomization to the first documented disease progression or death, whichever occurred first. Progression was based on tumor assessment made by the investigator according to the RECIST criteria

    Time frame: up to approximately 2 years

  3. Objective Response Rate (ORR)

    Proportion of subjects who have a complete or partial response relative to baseline as assessed per RECIST 1.1 criteria as well as Gynecologic Cancer Intergroup (GCIG) cancer antigen (CA)-125 criteria.

    Time frame: up to approximately 2 years

  4. Overall Survival (OS)

    OS is the time interval from the date of randomization to death from any cause.

    Time frame: up to approximately 3 years

  5. EQ-5D-5L questionnaire

    EQ-5D-5L is a questionnaire that focus on issues specific to ovarian cancer.

    Time frame: up to approximately 2 years

  6. FOSI-8 questionnaire

    FOSI-8 is a questionnaire that focus on issues specific to ovarian cancer.

    Time frame: up to approximately 2 years

07

Study locations

1 of 1 sites recruiting
  • Sun Yat-sen University
    Guangzhou, Guangdong 510000, China
    Recruiting
    • Xin Huang, professor · Contact
    • Chunyan Lan, professor · Contact
08

References and documents

Individual participant data

Plan to share: No — All clinical study findings and documents will be regarded as confidential. The investigator and members of his/her research team must not disclose such information without prior written approval from the sponsor.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2019 (actual). Primary completion is estimated for Jan 2021, 17 months after the start.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's planned 17 months is below that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2019
First posted
Jun 27, 2019
StartActual
Aug 16, 2019
Primary completionEst.
Jan 2021
CompletionEst.
Jul 2022
Last update
Oct 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04000295
Responsible party
Sponsor
First posted
Jun 27, 2019
Start date
Aug 16, 2019
Primary completion
Jan 2021 (estimated)
Completion
Jul 2022 (estimated)
Last update
Oct 8, 2019

Study contacts

Zhaoyu Zhong, M.M
Contact
zhongzhaoyu@hrglobe.cn
+86 15045090779
Lanjun Zhao, Ph.D
Contact
zhaolanjun@hrglobe.cn
+86 13331180196

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Apatinib · Etoposide

Start the discussion